Wantai Biological: Subsidiary's nine-valent HPV vaccine production line passes Turkey GMP inspection

Wantai Biological announced that its wholly-owned subsidiary Xiamen Wantai Canghai Biotechnology Co., Ltd.'s nine-valent human papillomavirus vaccine production line passed the GMP compliance inspection of the Turkish Medicines and Medical Devices Agency and was issued a GMP certificate, with the certificate issuance date being September 30, 2026. Turkey is a PIC/S member country. This is the first time the company's production and quality management system has passed a GMP compliance inspection of a PIC/S member country, which will have a positive impact on the overseas market expansion of the nine-valent HPV vaccine, but there is uncertainty regarding product approval and overseas sales.